262 related articles for article (PubMed ID: 26300318)
1. Nonalcoholic fatty liver disease: Roles of the gut and the liver and metabolic modulation by some dietary factors and especially long-chain n-3 PUFA.
Delarue J; Lallès JP
Mol Nutr Food Res; 2016 Jan; 60(1):147-59. PubMed ID: 26300318
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans.
Kelley NS
Metab Syndr Relat Disord; 2016 Nov; 14(9):417-430. PubMed ID: 27710160
[TBL] [Abstract][Full Text] [Related]
3. Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children: where do we stand?
Spooner MH; Jump DB
Curr Opin Clin Nutr Metab Care; 2019 Mar; 22(2):103-110. PubMed ID: 30601174
[TBL] [Abstract][Full Text] [Related]
4. Potential for dietary ω-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer.
Jump DB; Depner CM; Tripathy S; Lytle KA
Adv Nutr; 2015 Nov; 6(6):694-702. PubMed ID: 26567194
[TBL] [Abstract][Full Text] [Related]
5. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
6. Gut microbiome and nonalcoholic fatty liver diseases.
Zhu L; Baker RD; Baker SS
Pediatr Res; 2015 Jan; 77(1-2):245-51. PubMed ID: 25310763
[TBL] [Abstract][Full Text] [Related]
7. Omega-3 Fatty Acids and Gut Microbiota: A Reciprocal Interaction in Nonalcoholic Fatty Liver Disease.
Shama S; Liu W
Dig Dis Sci; 2020 Mar; 65(3):906-910. PubMed ID: 32036510
[TBL] [Abstract][Full Text] [Related]
8. A metabolomic analysis of omega-3 fatty acid-mediated attenuation of western diet-induced nonalcoholic steatohepatitis in LDLR-/- mice.
Depner CM; Traber MG; Bobe G; Kensicki E; Bohren KM; Milne G; Jump DB
PLoS One; 2013; 8(12):e83756. PubMed ID: 24358308
[TBL] [Abstract][Full Text] [Related]
9. Omega-3 PUFA modulate lipogenesis, ER stress, and mitochondrial dysfunction markers in NASH - Proteomic and lipidomic insight.
Okada LSDRR; Oliveira CP; Stefano JT; Nogueira MA; Silva IDCGD; Cordeiro FB; Alves VAF; Torrinhas RS; Carrilho FJ; Puri P; Waitzberg DL
Clin Nutr; 2018 Oct; 37(5):1474-1484. PubMed ID: 29249532
[TBL] [Abstract][Full Text] [Related]
10. Oxidative Stress and Non-Alcoholic Fatty Liver Disease: Effects of Omega-3 Fatty Acid Supplementation.
Yang J; Fernández-Galilea M; Martínez-Fernández L; González-Muniesa P; Pérez-Chávez A; Martínez JA; Moreno-Aliaga MJ
Nutrients; 2019 Apr; 11(4):. PubMed ID: 31003450
[TBL] [Abstract][Full Text] [Related]
11. Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids.
Arendt BM; Comelli EM; Ma DW; Lou W; Teterina A; Kim T; Fung SK; Wong DK; McGilvray I; Fischer SE; Allard JP
Hepatology; 2015 May; 61(5):1565-78. PubMed ID: 25581263
[TBL] [Abstract][Full Text] [Related]
12. [A Future Perspective on the Involvement of n-3 Polyunsaturated Fatty Acid in the Development of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis].
Nakamoto K; Obata T; Hirasawa A; Kim KI; Kim SR; Tokuyama S
Yakugaku Zasshi; 2016; 136(4):583-9. PubMed ID: 27040343
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis.
Li YH; Yang LH; Sha KH; Liu TG; Zhang LG; Liu XX
World J Gastroenterol; 2015 Jun; 21(22):7008-13. PubMed ID: 26078579
[TBL] [Abstract][Full Text] [Related]
14. Variation in the Plasma Levels of Polyunsaturated Fatty Acids in Control vis-à-vis Nonalcoholic Fatty Liver Disease Subjects and Its Possible Association with Gut Microbiome.
Vernekar M; Singhal R; Joshi K; Amarapurkar D
Metab Syndr Relat Disord; 2018 Sep; 16(7):329-335. PubMed ID: 29873593
[TBL] [Abstract][Full Text] [Related]
15. Gut Microbiota of Nonalcoholic Fatty Liver Disease.
Abdou RM; Zhu L; Baker RD; Baker SS
Dig Dis Sci; 2016 May; 61(5):1268-81. PubMed ID: 26898658
[TBL] [Abstract][Full Text] [Related]
16. Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.
Jump DB; Lytle KA; Depner CM; Tripathy S
Pharmacol Ther; 2018 Jan; 181():108-125. PubMed ID: 28723414
[TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic Fatty Liver Disease and the Gut Microbiome.
Boursier J; Diehl AM
Clin Liver Dis; 2016 May; 20(2):263-75. PubMed ID: 27063268
[TBL] [Abstract][Full Text] [Related]
18. Rodent Models of Nonalcoholic Fatty Liver Disease.
Zhong F; Zhou X; Xu J; Gao L
Digestion; 2020; 101(5):522-535. PubMed ID: 31600750
[TBL] [Abstract][Full Text] [Related]
19. Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence.
Federico A; Dallio M; Godos J; Loguercio C; Salomone F
Transl Res; 2016 Jan; 167(1):116-24. PubMed ID: 26318867
[TBL] [Abstract][Full Text] [Related]
20. Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease.
Musa-Veloso K; Venditti C; Lee HY; Darch M; Floyd S; West S; Simon R
Nutr Rev; 2018 Aug; 76(8):581-602. PubMed ID: 29917092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
